Obiltoxaximab
Obiltoxaximab (ETI-204, trade name Anthim) is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | Bacillus anthracis anthrax |
Clinical data | |
Trade names | Anthim |
Other names | ETI-204 |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6444H9994N1734O2022S44 |
Molar mass | 145521.59 g·mol−1 |
This drug was developed by Elusys Therapeutics, Inc.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.